Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Eiger BioPharmaceuticals, Inc. EIGR
$1.04
-$0.08 (-7.96%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
49611968.00000000
-
week52high
9.89
-
week52low
0.75
-
Revenue
13484000
-
P/E TTM
-1
-
Beta
1.88546700
-
EPS
-2.58000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 09 авг 2021 г. |
| Wedbush | Outperform | Outperform | 03 апр 2020 г. |
| Ladenburg Thalmann | Buy | Buy | 22 янв 2020 г. |
| Citigroup | Buy | 26 июн 2019 г. | |
| Baird | Outperform | 29 янв 2019 г. | |
| BTIG | Buy | Buy | 07 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Apelian David | A | 170000 | 170000 | 31 янв 2023 г. |
| Mayer Eldon C. III | A | 31500 | 31500 | 26 янв 2023 г. |
| Atkisson Erik | A | 26750 | 26750 | 26 янв 2023 г. |
| Dietz Thomas John | A | 50000 | 50000 | 23 янв 2023 г. |
| Murray Christine | D | 11000 | 5000 | 29 дек 2022 г. |
| Glenn Jeffrey S | A | 182355 | 100000 | 22 дек 2022 г. |
| Dietz Thomas John | D | 21000 | 22500 | 22 дек 2022 г. |
| Apelian David | D | 11000 | 5000 | 16 авг 2022 г. |
| Kelly-Croswell Lisa | A | 30000 | 30000 | 18 июл 2022 г. |
| Mayer Eldon C. III | D | 60468 | 1657 | 14 мар 2022 г. |
Новостная лента
EIGR Stock: 23.53% Surge Explanation
Pulse2
09 февр 2023 г. в 22:35
The stock price of Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) surged by 23.53% today. This is why.
7 Cheap But Risky Biotech Stocks
Barrons
18 янв 2023 г. в 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Best Penny Stocks To Buy? 4 To Watch Before 2023
PennyStocks
29 дек 2022 г. в 14:07
Penny stocks to watch before next year. The post Best Penny Stocks To Buy?
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
PennyStocks
28 дек 2022 г. в 13:16
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
PRNewsWire
07 дек 2022 г. в 16:05
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.